Hydroxychloroquine

"Hydroxychloroquine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)

Descriptor ID	D006886
MeSH Number(s)	D03.633.100.810.050.180.350
Concept/Terms	Hydroxychloroquine Hydroxychloroquine Oxychlorochin Oxychloroquine Hydroxychlorochin Plaquenil Plaquenil Hydroxychloroquine Sulfate Hydroxychloroquine Sulfate Hydroxychloroquine Sulfate (1:1) Salt

Below are MeSH descriptors whose meaning is more general than "Hydroxychloroquine".

Chemicals and Drugs [D]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, Fused-Ring [D03.633]
Heterocyclic Compounds, 2-Ring [D03.633.100]
Quinolines [D03.633.100.810]
Aminoquinolines [D03.633.100.810.050]
Chloroquine [D03.633.100.810.050.180]
Hydroxychloroquine [D03.633.100.810.050.180.350]

Below are MeSH descriptors whose meaning is related to "Hydroxychloroquine".

Below are MeSH descriptors whose meaning is more specific than "Hydroxychloroquine".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Hydroxychloroquine" by people in this website by year, and whether "Hydroxychloroquine" was a major or minor topic of these publications.

Bar chart showing 7 publications over 4 distinct years, with a maximum of 4 publications in 2014

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2013	0	1	1
2014	4	0	4
2020	0	1	1
2021	1	0	1

Below are the most recent publications written about "Hydroxychloroquine" by people in Profiles.

Coppock D, Baram M, Chang AM, Henwood P, Kubey A, Summer R, Zurlo J, Li M, Hess B. COVID-19 treatment combinations and associations with mortality in a large multi-site healthcare system. PLoS One. 2021; 16(6):e0252591.

View in: PubMed
Qaseem A, Yost J, Etxeandia-Ikobaltzeta I, Humphrey LL. Update Alert 2: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians. Ann Intern Med. 2020 09 01; 173(5):W88-W89.

View in: PubMed
Rosenfeld MR, Ye X, Supko JG, Desideri S, Grossman SA, Brem S, Mikkelson T, Wang D, Chang YC, Hu J, McAfee Q, Fisher J, Troxel AB, Piao S, Heitjan DF, Tan KS, Pontiggia L, O'Dwyer PJ, Davis LE, Amaravadi RK. A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. Autophagy. 2014 Aug; 10(8):1359-68.

View in: PubMed
Rangwala R, Leone R, Chang YC, Fecher LA, Schuchter LM, Kramer A, Tan KS, Heitjan DF, Rodgers G, Gallagher M, Piao S, Troxel AB, Evans TL, DeMichele AM, Nathanson KL, O'Dwyer PJ, Kaiser J, Pontiggia L, Davis LE, Amaravadi RK. Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma. Autophagy. 2014 Aug; 10(8):1369-79.

View in: PubMed
Rangwala R, Chang YC, Hu J, Algazy KM, Evans TL, Fecher LA, Schuchter LM, Torigian DA, Panosian JT, Troxel AB, Tan KS, Heitjan DF, DeMichele AM, Vaughn DJ, Redlinger M, Alavi A, Kaiser J, Pontiggia L, Davis LE, O'Dwyer PJ, Amaravadi RK. Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma. Autophagy. 2014 Aug; 10(8):1391-402.

View in: PubMed
Vogl DT, Stadtmauer EA, Tan KS, Heitjan DF, Davis LE, Pontiggia L, Rangwala R, Piao S, Chang YC, Scott EC, Paul TM, Nichols CW, Porter DL, Kaplan J, Mallon G, Bradner JE, Amaravadi RK. Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma. Autophagy. 2014 Aug; 10(8):1380-90.

View in: PubMed
Kiriakidou M, Cotton D, Taichman D, Williams S. Systemic lupus erythematosus. Ann Intern Med. 2013 Oct 1; 159(7):ITC4-1.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement